Home
Goodwin Procter LLP
Molly Grammel
Molly Grammel
Goodwin Procter LLP
Regeneron Files First BPCIA Complaint Regarding Biosimilar Eylea Against Mylan In West Virginia District Court
04 Aug 2022 | United States
CA Gov. Newsom Announces Budget Approval For Biosimilar Insulin Initiative
14 Jul 2022 | United States
20%
Very Popular: This author falls within the Top 20% for the below topics and industry categories
Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States for the topics, user groups and industry sectors listed below*:
Topics
  • Patent
  • Intellectual Property
  • Food, Drugs, Healthcare, Life Sciences
  • Life Sciences, Biotechnology & Nanotechnology
Positions
  • Inhouse Counsel, Lawyer in Company/Government
Industry
  • Pharmaceuticals & BioTech
* Rankings are based on analysis of the last 12 months of Mondaq readership data across more than 25,000 contributing authors. To be ranked ‘Very Popular’ an author must be in the top 20% of results within the selected criteria.
Contact Details
New York
Email Website
The New York Times Building
620 Eighth Avenue
New York
United States
Telephone: 1-212-8138800

  © Mondaq® Ltd 1994 - 2022. All Rights Reserved.